Tuesday 17th October 2023, Optos, Plc, the leading retinal imaging company, today announces the advances of Ultra-widefield Multimodal Retinal Imaging, a central focus of Optos’ satellite symposia at EURETINA 2023.
Optos, is recognised as a leading retinal imaging company. Optos’ devices capture ultra-widefield (UWF™) high-resolution optomap® images of 200◦ of the retina, something no other device can do in a single image. At EURETINA, Optos unveiled their latest innovations, including the Optos California’s new red/green/blue (rgb) color UWF™ imaging modality and the Optos Silverstone, an integration of swept-source OCT alongside UWF imaging.
Anne Marie Cairns, Chief Clinical Officer, at Optos said: “We are thrilled with the incredible discussions and insights shared at EURETINA 2023. It was a great opportunity to engage with experts and receive the positive reception and enthusiasm from attendees. We look forward to building on this momentum and driving innovation to benefit patients and the field of ophthalmology.”
To deepen understanding of the transformative impact of Optos devices on clinical care, Optos hosted a satellite symposium titled “Advances in Ultra-widefield Multimodal Retinal Imaging - Learn from our Experts", moderated by Prof. Srinivas Sadda, Professor of Ophthalmology – University of California Los Angeles (UCLA) and Director of Artificial Intelligence & Imaging Research – Doheny Eye Institute.
The symposium featured presentations and case studies from esteemed global ophthalmologists: Prof. Srinivas Sadda, Dr. Ali Erginay, Miss Vasuki Sivagnanavel, and Prof. Paulo Stanga. These experts explored various facets of Ultra-widefield Multimodal Retinal Imaging, shedding light on critical case studies and advancements.
Prof. Srinivas Sadda, Professor of Ophthalmology – University of California Los Angeles (UCLA), David Geffen School of Medicine and Director of Artificial Intelligence & Imaging Research – Doheny Eye Institute, on his topic of ‘Emerging Treatments and 1st Line Diagnostics for Geographic Atrophy’ said: “This is an exciting time in the space, particularly for Geographic atrophy. The emergence of therapies for atrophy, has really heightened the importance of having these diagnostic strategies to identify the monitor that we need to build to do this at scale. Because this kind of ultra-wide field imaging is available, it is going to be a particularly useful tool for us identifying patients who might be eligible for therapy.”
The Optos booth was attended regularly by attendees who wanted to see the California, Monaco, and Silverstone OCT in action. The symposia attracted an enthusiastic audience of professionals, with over 200 attendees present, eager to delve into the key clinical indications for Ultra-widefield Multimodal Retinal Imaging.
For more information about Optos, please visit www.optos.com. optomap image modalities may be seen on optomap Recognizing Pathology.
- ENDS -
Notes to editors:
Further quotes from global ophthalmologist that attended the Symposium
Dr Ali Erginay, Senior Consultant Ophthalmologist at Lariboisière Hospital, Paris, explored his topic of “Introducing optomap® Ultra-widefield Colour Red-Green-Blue Multimodal Imaging” as part of the Symposium. He said, “We had the privilege of using the new Optos RGB system for over a year now and were very surprised by its enhanced capabilities in penetrating a better range of media. The images can be clearly seen from the test results and where it is not just about the beauty of it, but about the efficiency of the diagnosis.”
Miss Vasuki Sivagnanavel, Consultant Ophthalmologist at Kingston Hospital NHS Foundation Trust, led the topic on “The Role of Ultra-Widefield Swept-Source OCT as an Integral Part of Patient Clinical Care Within a Busy NHS Unit and The Benefits It Has Brought”. Miss Sivagnanavel said, “Silverstone has just been released in the UK, just around the time of COVID emerging. It was pretty clear that the advantages of multimodal imaging were the ability to capture multiple data points, multiple data types, with the minimum acquisition time, and movement that meant minimum exposure for patients' adopters."
Prof. Paulo Stanga, Director & Vitreoretinal Surgeon - The Retina Clinic London and Institute of Ophthalmology at University College London (UCL), discussed the topic “Clinical Benefits of a New Imaging Technology for Simultaneous Multiwavelength-UWF Fundus Fluorescein Angiography and Indocyanine Green Angiography with Navigated Central and Peripheral SS-OCT”. Prof Stanga said, “Navigated peripheral OCT will give you cross-sectional information of the peripheral retina, the choroid, at a very good current, and the peripheral vitreoretinal interface. It is so extremely useful from a diagnostic point of view, but also from a medical legal point of view to have an adequate documentation of what we see at the time."
About Optos
Optos, a subsidiary of Nikon Corporation, is the leading retinal imaging company. Its core technology, ultra-widefield (UWF™) high-resolution digital images (optomap) capture approximately 82% and 200◦ of the retina, something no other device can do in a single image.
Optos has also developed integrated ultra-widefield retinal imaging with image-guided Optical Coherence Tomography (OCT). Optos devices facilitate the early detection, management, and effective treatment of disorders and diseases evidenced in the retina such as retinal detachments and tears, glaucoma, diabetic retinopathy, and age-related macular degeneration.
More than 2,000 published clinical studies show the long-term value of optomap imaging with OCT in diagnosis, treatment planning, and patient engagement.
For more information or interview requests, contact:
Joanna Ly, OVID Health
Joanna.ly@ovidhealth.co.uk or Optos@ovidhealth.co.uk